

Member FINRA/SIPC

Toll Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 1 N. Federal Highway, 5th floor ♦ Boca Raton, FL 33432

December 5, 2016

Sonoma Pharmaceuticals, Inc.
(SNOA/NASDAQ/\$4.90/Not rated)

Sherry Grisewood, CFA
Managing Partner, Life Science
Research
561-208-2943

Oculus Innovative Sciences Announces Name Change

In their most recent conference call, Oculus management notified investors that the Company would institute a change of corporate identity aimed at driving increased shareholder value by focusing on high margin dermatology products. This morning, Oculus issued a press release announcing that on December 6, 2016, the Company's name will officially change to Sonoma Pharmaceuticals. The stock will trade under the new symbol, SNOA, and warrants will trade under the symbol, SNOAW. The Company has also announced that concurrently with the name change, the Company's website will change to www.sonomapharma.com, effective December 6th.

The realignment of resources which included the divestiture of non-core foreign assets last month and now the unveiling of a new specialty pharma corporate identity completes this phase of the strategic turnaround plan that management instituted in 2014. Going forward, Sonoma intends to be highly focused on the US prescription dermatology and advanced skin care markets. In adopting a new corporate identity and more narrow corporate focus, management hopes the Company will be better understood by analysts and investors, and its shareholder value based upon its high margin, innovative prescription-based product set. SG



Company Notes provide current information we believe might be noteworthy to investors regarding the subject companies. Company Notes are not intended to be complete research reports. More detailed information concerning the rated companies referenced in this Note, including the full reports, basis for price targets and other disclosures, may be found at: http://dawsonjames.com/research_coverage.

Important Disclosures:

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject companies. The Firm has engaged in investment banking relationships with OCLS in the prior 12 months, as a manager or co-manager of a public offering and has received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from each of the subject companies. The Firm may have received other compensation from the subject companies in the last 12 months for services unrelated to investment banking.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of November 30, 2016, the Firm as a whole **beneficially owned 1%** or more of any class of common equity securities of any of the subject company (s) of this report. The Firm, its officers, directors, analysts or employees may effect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the companies subject to this report. The Firm may effect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Ratings Definitions:

- 1) **Buy:** the analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** the analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** the analyst believes the price of the stock will decline by at least 20% over the next

12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	2	22%	1	50%
Market Perform (Neutral)	1	11%	1	100%
Market Underperform (Sell)	0	0%	0	0%
Rating Suspensions*	6	67%	5	71%
Total	9	100%	7	22%

*Suspensions are ratings under review for possible change due to unusual market-moving news, and/or analyst departure/change

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.